Johnson & Johnson has secured a positive reimbursement decision in the UK for Imbruvica (ibrutinib), in the first-line treatment of chronic lymphocytic leukemia 21 April 2023
Privately-held Swiss firm Ferring Pharmaceuticals has entered into a new strategic collaboration in women’s health with the BioInnovation Institute (BII). 18 April 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.